Can thalidomide improve outcome in patients with multiple myeloma? Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 11, 2006, Pages 590-591

  Richardson, Paul G ^a   Mitsiades, Constantine S ^a,b   Munshi, Nikhil C ^a,c   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; DEXAMETHASONE; INTERFERON; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTESTINE OBSTRUCTION; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NEUROTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; SHORT SURVEY; STATISTICAL SIGNIFICANCE; SYNCOPE; THROMBOEMBOLISM; TREMOR;

EID: 33750549263     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0630     Document Type: Short Survey

References (8)

1. Munshi NC and Anderson KC (2005) To transplant or not to transplant? Blood 106: 3687-3688
2. Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
3. Richardson P et al. (2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79: 875-882
4. Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067
5. Rajkumar SV et al. (2006) Phase III clinical trial of thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431-436
6. Attal M et al. ((2006) Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood Jul 27 [Epub ahead of print]
7. Barlogie B et al. (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633-2638
8. Palumbo A et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367: 825-831